Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company, primarily focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer.?
| Revenue (Most Recent Fiscal Year) | $0.02M |
| Net Income (Most Recent Fiscal Year) | $-257.59M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1985.40 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.67 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1168850.00% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -52.98% |
| Return on Assets (Trailing 12 Months) | -41.28% |
| Current Ratio (Most Recent Fiscal Quarter) | 9.71 |
| Quick Ratio (Most Recent Fiscal Quarter) | 9.71 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.76 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.28 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.24 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.23 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 218.73M |
| Free Float | 189.86M |
| Market Capitalization | $258.10M |
| Average Volume (Last 20 Days) | 3.91M |
| Beta (Past 60 Months) | 0.60 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 13.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 83.63% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |